Abstract
Human immunodeficiency virus type 1 (HIV-1) is associated with persistent and progressive infection in the majority of untreated persons, with an average time of 10 yr until the development of acquired immune deficiency syndrome (AIDS). However, longitudinal cohort studies have now identified persons who have been infected for >20 yr without the development of disease. In fact, a small number of untreated infected persons have maintained viral loads at or below the limits of detection by the most sensitive assays now available, normal CD4 cell counts, and have had no evidence of disease manifestations related to HIV. Other human viral infections such as Epstein—Barr virus (EBV) and Cytomegalovirus (CMV) persist for the life of an infected person, but are held in check by a persistent and effective immune response. The existence of persons with chronic controlled HIV-1 infection suggests that a state of immunologic control may be achievable in this infection as well.
Keywords
- Human Immunodeficiency Virus
- Human Immunodeficiency Virus Infection
- Acquire Immune Deficiency Syndrome
- Simian Immunodeficiency Virus
- Acute Human Immunodeficiency Virus Infection
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Goulder PJR, Rowland SL, McMichael AJ, Walker BD. Anti-HIV cellular immunity: recent advances towards vaccine design. AIDS 1999; 13: s121 – s36.
Yang 00, Kalams SA, Rosenzweig M, Trocha A, Jones N, Koziel M, et al. Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes. J Virol 1996; 70: 5799–806.
Yang 00, Tran AC, Kalams SA, Johnson RP, Roberts MR, Walker BD. Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells. Proc Natl Acad Sci USA 1997; 94: 11478–83.
Klein MR, van Baalen CA, Holwerda AM, Kerkhof Garde SR, Bende RJ, Keet IP, et al. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995; 181: 1365–72.
Rinaldo C, Huang X-L, Fan Z, Ding M, Beltz L, Logar A, et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol 1995; 69: 5838–42.
Harrer T, Harrer E, Kalams SA, Barbosa P, Trocha A, Johnson RP, et al. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J Immunol 1996; 156: 2616–23.
Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses [comment]. J Exp Med 1998; 188: 2199–204.
Ahmed R, Butler LD, Bhatti L. T4+ T helper cell function in vivo: differential requirement for induction of antiviral cytotoxic T-cell and antibody responses. J Virol 1988; 62: 2102–6.
Rahemtulla A, Fung-Leung WP, Schilham MW, Kundig TM, Sambhara SR, Narendran A, et al. Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4. Nature 1991; 353: 180–4.
Matloubian M, Concepcion RJ, Ahmed R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol 1994; 68: 8056–63.
Battegay M, Moskophidis D, Rahemtulla A, Hengartner H, Mak TW, Zinkernagel RM. Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice. J Virol 1994; 68: 4700–4.
von Herrath MG, Yokoyama M, Dockter J, Oldstone MB, Whitton JL. CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J Virol 1996; 70: 1072–9.
Cardin RD, Brooks JW, Sarawar SR, Doherty PC. Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells. J Exp Med 1996; 184: 863–71.
Hasenkrug KJ, Brooks DM, Dittmer U. Critical role for CD4(+) T cells in controlling retrovirus replication and spread in persistently infected mice. J Virol 1998; 72: 6559–64.
Gerlach JT, Diepolder HM, Jung MC, Gruener NH, Schraut WW, Zachoval R, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C [see comments]. Gastroenterology 1999; 117: 933–41.
Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-Tcell responses is mediated by CD40 signalling [see comments]. Nature 1998; 393: 478–80.
Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions [see comments]. Nature 1998; 393: 480–3.
Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999; 283: 857–60.
Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J, et al. Dramatic Rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999; 189: 991–8.
Ogg GS, Jin X, Bonhoeffer S, Dunbar PR, Nowak MA, Monard S, et al. Quantitation of HIV-1specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998; 279: 2103–6.
Koup RA, Hesselton RM, Safrit JT, Somasundaran M, Sullivan JL. Quantitative assessment of human immunodeficiency virus type 1 replication in human xenografts of acutely infected HuPBL-SCID mice. AIDS Res Hum Retrovir 1994; 10: 279–84.
Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MBA. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol 1994; 68: 6103–10.
Rosenberg ES, Walker BD. HIV type 1-specific helper T cells: a critical host defense. AIDS Res Hum Retrovir 1998; 14:Suppl 2: S143–7.
Lane HC, Depper JM, Greene WC, Whalen G, Waldmann TA, Fauci AS. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med 1985; 313: 79–84.
Clerici M, Stocks NI, Zajac RA, Boswell RN, Bernstein DC, Mann DL, et al. Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals. Nature 1989; 339: 383–5.
Schwartz D, Sharma U, Busch M, Weinhold K, Matthews T, Lieberman J, et al. Absence of recoverable infectious virus and unique immune responses in an asymptomatic HIV+ long-term survivor. AIDS Res Hum Retrovir 1994; 10: 1703–11.
Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, et al. Vigorous HIV1-specific CD4+ T cell responses associated with control of viremia. Science 1997; 278: 1447–50.
Kalams SA, Buchbinder SP, Rosenberg ES, Billingsley JM, Colbert DS, Jones NG, et al. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J Virol 1999; 73: 6715–20.
Pitcher CJ, Quittner C, Peterson DM, Connors M, Koup RA, Maino VC, et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression [see comments]. Nat Med 1999; 5: 518–25.
Gauduin MC, Glickman RL, Ahmad S, Yilma T, Johnson RP. Characterization of SIV-specific CD4+ T-helper proliferative responses in macaques immunized with live-attenuated SIV. J Med Primatol 1999; 28: 233–41.
Abbas AK. Die and let live: eliminating dangerous lymphocytes. [Review] [15 refs]. Cell 1996; 84: 655–7.
Milich DR, Linsley PS, Hughes JL, Jones JE. Soluble CTLA-4 can suppress autoantibody production and elicit long term unresponsiveness in a novel transgenic model. J Immunol 1994; 153: 429–35.
Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells [see comments]. Nature 1993; 362: 758–61.
Klenerman P, Meier UC, Phillips RE, McMichael AJ. The effects of natural altered peptide ligands on the whole blood cytotoxic T lymphocyte response to human immunodeficiency virus. Eur J Immunol 1995; 25: 1927–31.
Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132: 296–305.
Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103–7.
Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY, et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999; 10: 439–49.
Lisziewicz J, Rosenberg E, Lieberman J, Jessen H, Lopalco L, Siliciano R, et al. Control of HIV despite the discontinuation of antiretroviral therapy [letter]. N Engl J Med 1999; 340: 1683–4.
Ortiz. Containment of breakthrough HIV plasma viremia in the absence of antiretroviral therapy is associated with a broad and vigorous HIV-specific CTL response. In: 6th Conference on Retro-viruses and Opportunistic Infections, 1999; Chicago, 1999.
Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277: 112–6.
Kelleher AD, Can A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996; 173: 321–9.
Angel JB, Kumar A, Parato K, Filion LG, Diaz-Mitoma F, Daftarian P, et al. Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir. J Infect Dis 1998; 177: 898–904.
Connors M, Kovacs JA, Krevat S, Gea-Banacloche JC, Sneller MC, Flanigan M, et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies [see comments]. Nat Med 1997; 3: 533–40.
Gotch F, Hardy G, Imami N. Therapeutic vaccines in HIV.1 infection. Immunol Rev 1999; 170: 173–82.
Dhodapkar MV, Steinman RM, Sapp M, Desai H, Fossella CF, Krasovsky J, et al. Rapid generation of broad T-cell immunity in humans after a single injection of maturation dendritic cells. J Clin Invest 1999; 104: 173–80.
Greenough TC, Sullivan JL, Desrosiers RC. Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1 [letter]. N Engl J Med 1999; 340: 236–7.
Klenerman P, Zinkernagel RM. Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes [see comments]. Nature 1998; 394: 482–5.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Walker, B.D. (2001). Characterization of the HIV-1-Specific T-Helper Cell Response. In: Pantaleo, G., Walker, B.D. (eds) Retroviral Immunology. Infectious Disease. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-110-7_10
Download citation
DOI: https://doi.org/10.1007/978-1-59259-110-7_10
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-128-8
Online ISBN: 978-1-59259-110-7
eBook Packages: Springer Book Archive